Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Joon Oh Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6502-2612; OpenAlex author ID A5045587524. Sources: ClinicalTrials.gov.

Their work

Papers
40 (first author 0, last author 9)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
171
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: 3 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers, 1 trial · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 40

  1. Prediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study. Co-author DOI 10.1016/j.amepre.2025.107979↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  4. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  5. Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age… Co-author DOI 10.1200/jco-25-01169↗
  6. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  7. L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. Last author DOI 10.1038/s41598-025-07668-1↗
  8. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  9. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  10. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  11. Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study. Last author DOI 10.6004/jnccn.2023.7060↗
  12. Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. Last author DOI 10.1016/j.ejca.2021.12.027↗
  13. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Last author DOI 10.1053/j.gastro.2021.09.070↗
  14. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  15. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  16. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  17. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicent… Co-author DOI 10.1016/j.esmoop.2021.100049↗
  18. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Last author DOI 10.1177/17588359211038478↗
  19. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  20. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  21. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  22. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  23. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
  24. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  25. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Co-author DOI 10.1200/jco.19.01890↗
  26. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  27. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  28. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  29. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  30. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
  31. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  32. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. Last author DOI 10.1186/s12885-018-4995-0↗
  33. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  34. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00259-016-3316-6↗
  35. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  36. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-013-2328-1↗
  37. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Last author DOI 10.1097/coc.0b013e31821a83d7↗
  38. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Co-author DOI 10.2217/pgs.12.82↗
  39. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Last author DOI 10.1158/1535-7163.mct-11-0269↗
  40. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Last author DOI 10.1159/000328449↗

Trials 1

  1. Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas Principal investigator NCT05557851↗

Closest collaborators

The 25 strongest of 171 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jung Yong Hong · 10 shared papers, 2014–2026 · strength 2.07
  2. Young Suk Park · 12 shared papers, 2011–2026 · strength 1.69
  3. Jin Seok Heo · 11 shared papers, 2018–2025 · strength 1.26
  4. Joo‐Hyun Park · 5 shared papers, 2022–2026 · strength 1.24
  5. In Woong Han · 8 shared papers, 2020–2025 · strength 1.07
  6. Joo Kyung Park · 8 shared papers, 2018–2025 · strength 0.97
  7. Song Cheol Kim · 8 shared papers, 2018–2026 · strength 0.97
  8. Ho Yeong Lim · 7 shared papers, 2011–2026 · strength 0.84
  9. Kyungdo Han · 3 shared papers, 2022–2026 · strength 0.74
  10. Eunsung Jun · 5 shared papers, 2020–2026 · strength 0.72
  11. Daniel D. Von Hoff · 5 shared papers, 2020–2026 · strength 0.69
  12. Sang Hyun Shin · 4 shared papers, 2021–2025 · strength 0.65
  13. Seung Tae Kim · 6 shared papers, 2011–2025 · strength 0.61
  14. Hongbeom Kim · 5 shared papers, 2020–2025 · strength 0.59
  15. Do‐Youn Oh · 7 shared papers, 2018–2022 · strength 0.57
  16. Kyu Taek Lee · 5 shared papers, 2011–2025 · strength 0.57
  17. Erkut Hasan Borazanci · 4 shared papers, 2020–2026 · strength 0.56
  18. Teresa Mercade Macarulla · 6 shared papers, 2019–2022 · strength 0.55
  19. Jong Kyun Lee · 4 shared papers, 2012–2025 · strength 0.54
  20. Hee Chul Park · 4 shared papers, 2012–2025 · strength 0.54
  21. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  22. Ajay Goel · 3 shared papers, 2022–2026 · strength 0.52
  23. Jin‐Young Jang · 6 shared papers, 2018–2023 · strength 0.52
  24. Woo Jin Lee · 6 shared papers, 2018–2023 · strength 0.52
  25. Wooil Kwon · 6 shared papers, 2018–2023 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.